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Background: Beclometasone dipropionate is an inhaled corticosteroid (ICS) available in both
extrafine and larger-particle hydrofluoroalkane formulations. Extrafine beclometasone has
greater small airway distribution and inhalation technique tolerance than larger-particle be-
clometasone; therefore, its use may be associated with improved asthma outcomes at popu-
lation levels. The study objective was to compare real-life effectiveness of extrafine and
larger-particle beclometasone.
Methods: Retrospective matched cohort study including primary care patients with asthma
(ages 12e60 and non-smokers 61e80 years) prescribed extrafine or larger-particle beclometa-
sone by metered-dose inhaler. We studied patients receiving their first ICS (initiation popula-
tion, n Z 11,289) or switched from another ICS without dose change (switch population,
n Z 19,065). The extrafine and larger-particle beclometasone cohorts were matched in each
population for demographic and database measures of asthma control during a baseline year;
and endpoints assessed during 1 outcome year were adjusted for residual confounding factors.rimary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Fores-
þ44 1224 554588; fax: þ44 1224 550683.
Price).
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988 D. Price et al.Results: The odds of no loss of asthma control (no asthma-related hospital attendance, consul-
tation for lower respiratory tract infection, or oral corticosteroids) were significantly higher in
the extrafine beclometasone cohorts of both initiation population (adjusted odds ratio [aOR]
1.12; 95% CI 1.02e1.23) and switch population (aOR 1.10; 95% CI 1.01e1.19). The odds of bet-
ter adherence to ICS therapy were also significantly higher in both extrafine beclometasone co-
horts (initiation population, aOR 1.64; 95% CI 1.52e1.75 and switch population, aOR 1.35; 95%
CI 1.27e1.43).
Conclusions: These findings are consistent with the hypothesis that delivery of beclometasone
in extrafine particle size produces real-life asthma treatment benefits.
Clinical trials no. NCT01400217.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Beclometasone dipropionate is an inhaled corticosteroid
(ICS) that is available in both extrafine and larger-particle
formulations for administration by pressurised metered-
dose inhaler containing hydrofluoroalkane (HFA) propel-
lant. The mass median aerodynamic diameter particle size
of extrafine beclometasone is 1.1 microns, and that of
larger-particle beclometasone is 2.9 microns.1 Both are
formulated with beclometasone in solution, rather than in a
suspension as for the now discontinued chlorofluorocarbon
(CFC)-beclometasone.
Larger-particle beclometasone was deliberately engi-
neered by addition of glycerol to the formulation to enable
a “dose for dose” exchange when transferring from CFC to
HFA inhaler propellant. In 6- and 12-week clinical trials,
larger-particle beclometasone was equivalent in efficacy on
a microgram-for-microgram basis to CFC-beclometasone
with regard to asthma-related endpoints, with similar
safety and tolerability profiles.2
By contrast, extrafine beclometasone is licensed to be
prescribed at half the dose of the larger-particle beclo-
metasone formulations.1 Dose-ranging study results indi-
cate that extrafine beclometasone has significantly greater
effects on lung function than CFC-beclometasone on a
microgram-for-microgram comparison.3 The lung deposi-
tion of extrafine beclometasone is much greater than that
of CFC-beclometasone (55e60% compared with 4e7% for
CFC-beclometasone in healthy volunteers) and oropharyn-
geal deposition is lower (29e30% versus 90e94%).4e6 When
switched from CFC-beclometasone to extrafine beclome-
tasone at half the dose, patients in short-term randomised
controlled trials maintained similar degrees of asthma
control, with comparable safety profile, while those in a 12-
month pragmatic trial experienced significantly greater
improvement in health-related quality of life and a signifi-
cantly higher percentage of symptom-free days than pa-
tients maintained on CFC-beclometasone.7e12
Efficacy in randomised controlled trials, which study
tightly defined populations outside the normal ecology of
care, does not necessarily translate to effectiveness in a
real-life clinical setting, where factors that can influence
and interact with asthma-related outcomes include co-
morbidities, polypharmacy, smoking habits, poor inhaler
technique, and suboptimal adherence.13e16 Moreover, the
benefits of an extrafine formulation are not easy to test in a
controlled trial setting.17 Smokers are usually excludedfrom these trials, as are patients with poor adherence and/
or poor inhaler technique, and it would be unethical to
maintain a control group of patients at increased risk of
exacerbations without increasing their treatment. For
these reasons, real-life research is needed to understand
whether differences in ICS particle size and the associated
difference in airway deposition have an impact on asthma
outcomes in routine practice. An observational design can
enable the study of large numbers of patients, potentially
improving the generalisability of study results.17
The objective of this observational database study was
to compare the real-life effectiveness of extrafine and
larger-particle beclometasone for two populations of pri-
mary care patients with asthma: those who were prescribed
ICS for the first time and those switched from another ICS
with no change in CFC-beclometasone-equivalent dose. Our
hypothesis was that the potential benefits of improved total
and small airway deposition and lower oropharyngeal
deposition with extrafine beclometasone would translate to
better asthma-related outcomes (less unplanned health-
care use and fewer oral corticosteroid courses).Methods
Data sources and patients
This retrospective matched cohort study used patient data
contained in two computerised primary care databases in
the UK. The General Practice Research Database (GPRD),
now incorporated into the Clinical Practice Research
Datalink (CPRD) is well-validated and used frequently for
pharmaco-epidemiological research,18e21 and included
about 5 million active patients. The Optimum Patient Care
Research Database (OPCRD) contains anonymised,
research-quality data for 341,000 patients with respiratory
disease at approximately 300 practices that subscribe to
OPC for respiratory review services.22
Patients eligible for the study were 12e80 years old
when they initiated ICS therapy for asthma (initiation
population), or were switched with no change in CFC-
beclometasone-equivalent dose to new ICS therapy (switch
population), with a prescription for either extrafine
beclometasone (Qvar, Teva Pharmaceutical Industries Ltd.,
Petach Tikva, Israel) or larger-particle beclometasone
(Clenil Modulite, Chiesi Ltd, Highfield, Cheadle, UK) by
pressurised metered-dose inhaler. (Patients who received
Extrafine versus larger-particle BDP for asthma 989Qvar by breath-actuated inhaler were not eligible.) CFC-
beclometasone dose equivalency was calculated in the ra-
tios of 1:2:1:2:2 for larger-particle beclometasone, extra-
fine beclometasone, budesonide, fluticasone propionate,
and mometasone, respectively. Index prescription dates
began in 1998, when extrafine beclometasone became
available in the UK, and ended on October 31, 2009. To be
eligible for inclusion, patients had to have been registered
continuously for at least 2 years (1 baseline year before and
1 outcome year after the index date).
“Asthma” was defined as the presence of a diagnostic
code for asthma in the database or two or more pre-
scriptions for asthma (reliever or controller medication) on
at least two different dates during the baseline year. In
addition, to be eligible for the study, patients had to have
evidence of chronic asthma, defined as four or more res-
piratory prescriptions (namely, for a bronchodilator, ICS, or
leukotriene receptor antagonist) recorded in the database
at any time. To be eligible for the initiation population,
patients had to have ongoing asthma therapy, defined as
two or more ICS prescriptions during the outcome year
including the index prescription; to be eligible for the
switch population, patients had to have received at least
one prescription for ICS and at least one other asthma
prescription drug during the baseline year.
Smokers or ex-smokers older than 60 years were
excluded from the study to minimise the inclusion of pa-
tients with chronic obstructive pulmonary disease (COPD)
misdiagnosed as asthma. A diagnostic code for COPD or any
chronic respiratory disease other than asthma at any time
in the database was cause for exclusion from the study.
Other exclusion criteria were receipt of maintenance oral
corticosteroids during the baseline year or prescriptions on
the index date for multiple ICS. In addition, for the switch
population, patients were excluded if during the baseline
year they had been prescribed ICS via dry powder device or
a combination inhaler (ICS plus long-acting beta-agonist
[LABA]) in addition to their separate ICS inhaler. Pre-
scriptions for separate LABA inhalers were allowed.
Approval was given for use of the GPRD data by the GPRD
Independent Scientific Advisory Committee. The OPCRD has
been approved by Trent Multi Centre Research Ethics
Committee for clinical research use, and the study protocol
was approved by ADEPT (Anonymised Data Ethics Protocols
and Transparency Committee), OPC’s independent scienti-
fic advisory committee.Study endpoints
We used several composite database measures designed to
capture asthma-related outcomes during the outcome
year, listed and defined in Table 1. In addition to the co-
primary endpoint of no loss of asthma control, we evalu-
ated the more stringent measure of no loss of asthma
control plus limited short-acting b-agonist (SABA) use,
defined as no loss of asthma control plus SABA use limited
to salbutamol 200 mg/day or terbutaline 500 mg/day.
The definition for the co-primary endpoint of severe ex-
acerbations was based on the European Respiratory Soci-
ety/American Thoracic Society (ERS/ATS) Task Force
definition (see Table 1).23Adherence to ICS was defined as the percentage of a
year’s supply taken by the patient, calculated using pre-
scriptions (Table 1) and categorised as <50%; 50e69%,
70e99%, and 100%.24,25 In addition, we calculated the
controller-to-total asthma medication ratio, dichotomised
as <0.5 versus 0.5 (a ratio of 0.5 has been associated
with better disease control).26,27Statistical analyses
Study endpoints and the main analyses were established a
priori according to standard operating procedures of the
study group.28 Analyses were conducted using SPSS version
18 (SPSS Statistics, IBM, Somers, NY, USA), SAS version 9.2
(SAS Institute, Marlow, Buckinghamshire, UK), and Micro-
soft Office Excel 2007 (Microsoft, Bellevue, WA, USA). Sta-
tistical significance was defined as p < 0.05.
In the unmatched initiation population the extrafine
beclometasone cohort was larger whereas in the switch
population the reverse was the case (Fig. S1 in the Online
Supplement); consequently we matched patients in
extrafine:larger-particle beclometasone ratios of 2:1 in the
initiation population and 1:2 in the switch population to
maximise both the cohort sizes and the number of matched
groupings, and thus the power of statistical tests. We
matched on clinically and demographically significant
characteristics, namely, sex, age, and baseline asthma-
related factors, including acute courses of oral corticoste-
roids, average daily SABA dose, non-emergency asthma
consultations (namely, those not resulting in a course of
oral corticosteroids), and, for patients in the switch popu-
lation, average baseline daily ICS dose.
Summary statistics were used to describe baseline and
outcome variables, and heavily skewed data were cat-
egorised. Differences between matched cohorts at baseline
were determined using conditional logistic regression.
Statistical comparisons of ICS doses prescribed at the index
date and during the outcome year were made by doubling
extrafine beclometasone doses in line with the recom-
mended 1:2 prescribing dose ratio with larger-particle
beclometasone.1
The adjusted odds of no loss of asthma control during the
outcome year was compared between cohorts, with larger-
particle beclometasone as the reference treatment, using
conditional logistic regression to adjust for any residual con-
founding. The dichotomous outcome for no loss of asthma
control was used as the dependent variable, with treatment
and potential residual confounding factors as explanatory
variables. This approach was used also for comparisons be-
tween cohorts of the no loss of asthma control plus limited
SABA use endpoint. The total numbers of severe exacerba-
tions recorded during the outcome year were compared be-
tween treatment cohorts using a conditional Poisson
regression model to obtain estimates of exacerbation rates in
the extrafine beclometasone cohort relative to the larger-
particle beclometasone cohort. The model used empirical
standarderrors formore robustconfidence intervals (CIs), and
adjustments were made for residual baseline confounders. A
similar approach was used for comparison of other rates.
Conditional ordinal regression models were used to
compare cohorts for adjusted odds of higher SABA use and
Table 1 Definitions of the study endpoints, assessed over the outcome year.
Co-primary endpoints
No loss of asthma control, includes all of the following:
1. No asthma-relateda hospital attendance or admission, A&E attendance, out-of-hours attendance, or OPD attendance, and
2. No GP consultation for lower respiratory tract infection, and
3. No prescription for acute course of oral corticosteroids.
Number of severe exacerbations, defined as any of the following:
1. Acute course of oral corticosteroids, or
2. Asthma-related hospital attendance or admission or A&E attendance
Secondary endpoints
No loss of asthma control plus limited SABA use, includes all of the following:
1. No asthma-related hospital attendance or admission, A&E attendance, out-of-hours attendance, or OPD attendance, and
2. No GP consultation for lower respiratory tract infection, and
3. No prescription for acute course of oral corticosteroids, and
4. Average daily prescribed dose of 200 mg salbutamol or 500 mg terbutaline.
Number of lower respiratory episodes requiring medical resource use, defined as any of the following:
1. Acute course of oral corticosteroids, or
2. Asthma-related hospital attendance or admission, or A&E attendance, or
3. Asthma-related out-of-hours hospital attendance, or
4. GP consultation for lower respiratory tract infection.
Number of respiratory-related hospitalisations, defined as any of the following:
1. Inpatient admission for asthma, or
2. Inpatient admission with lower respiratory code.
Adherence to inhaled corticosteroid, defined as:
1. Number of days’ supply of inhaled corticosteroid/365  100%.
Controller-to-total asthma medication ratio, defined as:
1. Units of controllers/[units of controllers þ relievers]b
A&E Z Accident & Emergency; GP Z general practice; OPD Z Outpatient Department; SABA Z short-acting b-agonist.
a Asthma-related events in the database included all events with a lower respiratory code, including all asthma codes and lower
respiratory tract infection codes.
b One unit of controller was defined as one inhaled corticosteroid inhaler or one prescription for leukotriene receptor antagonist; one
unit of reliever was defined as one SABA inhaler.
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comes for average daily SABA dose and ICS adherence,
respectively, were used as the dependent variable, with
treatment and residual confounding factors as explanatory
variables.
For all outcome models, we assessed as potential con-
founding factors those baseline variables that were signifi-
cantly different or showed a trend towards a difference
(p < 0.10, conditional logistic regression) between the two
treatment cohorts; in addition, baseline variables that were
predictive (p < 0.05) of outcomes through multivariate
analysis were also considered as potential confounders
(please see full list considered in Supplemental Table S1).
We then adjusted each primary and secondary outcome for
the appropriate non-collinear baseline confounders. As all
primary outcome results were likely correlated, no correc-
tions were made for type I errors for multiple comparisons.
In an exploratory analysis to better understand the dif-
ference in outcomes, we drew on patient data contained in
the OPCRD to extrapolate the impact of ICS choice by
scaling our results to a population size of 340,900 patients,
the mean size of a UK Primary Care Trust (PCT).29 We
applied study inclusion criteria and results to annualised
data in the database in 2007 and compared the rates of
hospitalisations and oral corticosteroid courses that wouldresult from treatment with extrafine or larger-particle
beclometasone.
Results
Patients
A total of 11,289 patients were identified and matched in
extrafine:larger-particle beclometasone ratio of 2:1 in the
initiation population; and 19,065 were identified and
matched in ratio of 1:2 in the switch population (see Fig. S1
in the Online Supplement). Baseline characteristics of the
matched cohorts of both study populations are summarised
in Table 2 and baseline asthma-related parameters in Table
3.
In both populations at baseline the proportion of pa-
tients meeting the primary measure of no loss of asthma
control was similar in the two matched cohorts (Table 3).
The date of the index prescription was significantly earlier
in the extrafine beclometasone cohort because of the
earlier launch date (1998 versus 2006 for larger-particle
beclometasone). The proportions of smokers and ex-
smokers over 40 years old were similar in the matched co-
horts (Table 2). The few significant baseline differences
Table 2 Baseline demographic and clinical characteristics of patients with asthma receiving their first ICS prescription as
extrafine or larger-particle beclometasone by pMDI or switching ICS therapy to extrafine or larger-particle beclometasone by
pMDI.
Characteristic Initiation population Switch population
Extrafine BDP
(n Z 7526)
LP BDP
(n Z 3763)
p Valuea Extrafine BDP
(n Z 6355)
LP BDP
(n Z 12,710)
p Valuea
Female sex, n (%) 4618 (61.4) 2309 (61.4) n/a 3627 (57.1) 7254 (57.1) n/a
Age at index date, mean (SD) 41.2 (15.9) 41.0 (16.2) <0.001 43.5 (17.0) 43.4 (17.1) 0.409
12e60 y, n (%) 6732 (89.4) 3366 (89.4) n/a 5382 (84.7) 10,764 (84.7) n/a
Nonsmokers 61e80 y, n (%) 794 (10.6) 397 (10.6) n/a 973 (15.3) 1946 (15.3) n/a
BMI >30 kg/m2, n (%)b 2044 (30.1) 1049 (31.3) 0.308 1565 (26.7) 3337 (29.2) 0.007
Charlson comorbidity index, n (%)c
0 6662 (88.5) 3401 (90.4) 0.002 5533 (87.1) 11,252 (88.5) 0.002
1 864 (11.5) 362 (9.6) 822 (12.9) 1458 (11.5)
Recorded smoking status, n (%) 7458 (99.1) 3721 (98.9) 6302 (99.2) 12,638 (99.4)
Current smoker 1776 (23.8) 818 (22.0) 0.260 1222 (19.4) 2370 (18.8) 0.979
Ex-smoker 1420 (19.0) 716 (19.2) 1009 (16.0) 2072 (16.4)
Non-smoker 4262 (57.1) 2187 (58.8) 4071 (64.6) 8196 (64.9)
Current and ex-smokers
>40 years old
1576 (20.9) 774 (20.6) e 1259 (19.8) 2506 (19.7) e
Recorded comorbidity/treatment, n (%)d
Rhinitis 2276 (30.2) 1175 (31.2) 0.286 2197 (34.6) 4299 (33.8) 0.305
Cardiac disease 2215 (29.4) 1054 (28.0) 0.075 2102 (33.1) 4038 (31.8) 0.032
Gastro-oesophageal reflux 1586 (21.1) 960 (25.5) <0.001 1222 (19.2) 3053 (24.0) <0.001
1 prescription prior 12 mo, n (%)
NSAID 1666 (22.1) 894 (23.8) 0.047 1381 (21.7) 2906 (22.9) 0.066
Beta blocker 413 (5.5) 204 (5.4) 0.881 146 (2.3) 303 (2.4) 0.706
Paracetamol 1359 (18.1) 787 (20.9) <0.001 1329 (20.9) 2910 (22.9) 0.001
BDP Z beclometasone dipropionate; BMI Z body mass index; n/a Z not applicable (matching criterion); LP Z larger-particle;
NSAID Z non-steroidal anti-inflammatory drug; pMDI Z pressurised metered-dose inhaler.
a Conditional logistic regression.
b Not all patients had recorded weight and height data. In the initiation population, BMI n Z 6801 (90%) and 3359 (89%) for extrafine
and larger-particle beclometasone cohorts, respectively; in the switch population, BMI n Z 5858 (92%) and 11,411 (90%), respectively.
c The Charlson comorbidity index is a weighted index that accounts for number and severity of co-morbidities, each assigned a score
depending on the associated risk of dying.
d Patients with rhinitis, cardiac disease, and GERD included those with a recorded diagnosis or recorded therapy for same.
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significant; however, all baseline variables that were sta-
tistically significantly different between cohorts were
considered as potential residual confounders in the
adjusted outcomes analyses, as described above.Outcomes
In the initiation population on the index date, the prescribed
mean (SD) CFC-beclometasone-equivalent doses were 465
(229) and 411 (165) mg/d in the extrafine and larger-particle
beclometasone cohorts, respectively (p< 0.001), with actual
mean dose 232 (115) mg/d of extrafine beclometasone. In the
switch population, the index datemean CFC-beclometasone-
equivalent doses were 455 (168) and 474 (213) mg/d,
respectively (p < 0.001), with actual mean dose 228 (84) mg/
d of extrafine beclometasone. Fig. 1 depicts the index date
dose distribution in proportion according to the 1:2 dosing
recommendations.
Results for the primary and secondary outcome mea-
sures are depicted in Table 4 and Fig. 2. The percentages ofpatients meeting the no loss of asthma control measures
were greater in both extrafine beclometasone cohorts than
the corresponding larger-particle beclometasone cohort
(Table 4), and the adjusted ORs for both measures were
significantly higher for patients prescribed extrafine
beclometasone (Fig. 2). There were no significant differ-
ences between cohorts in the rate of severe exacerbations
after adjustment for residual baseline confounders (Fig. 2).
Respiratory-related hospitalisations were infrequent
overall (Table 4) but occurred at a significantly lower rate
in the extrafine beclometasone cohorts (Fig. 2). The me-
dian daily dose of SABA was the same in both cohorts of
each population (data not shown). In the switch population,
after adjustment for baseline confounding factors, patients
who received larger-particle beclometasone had signifi-
cantly higher odds of receiving a higher SABA dose.
Adherence to ICS therapy was significantly higher in both
extrafine beclometasone cohorts than the comparable
larger-particle beclometasone cohort (Fig. 2). Median ICS
doses taken during the outcome year were significantly
higher in both extrafine beclometasone cohorts (see Table
4). We further evaluated doseeresponse relationships in
Table 3 Asthma-related parameters and medical resource use during the baseline year before the index prescription date.
Characteristic Initiation population Switch population
Extrafine BDP
(n Z 7526)
LP BDP
(n Z 3763)
p Valuea Extrafine BDP
(n Z 6355)
LP BDP
(n Z 12,710)
p Valuea
Year of index prescription,
mean (SD)
2005 (2.7) 2008 (0.7) <0.001 2005 (2.6) 2008 (0.7) <0.001
Database code for asthma,b n (%) 7300 (97.0) 3585 (95.3) <0.001 6220 (97.9) 12,378 (97.4) 0.035
No loss of asthma control, n (%) 5036 (66.9) 2494 (66.3) 0.343 5171 (81.4) 10,372 (81.6) 0.589
Spacer device used, n (%) 548 (7.3) 405 (10.8) <0.001 584 (9.2) 1255 (9.9) 0.124
%predicted PEF, mean (SD)c 83.0 (19.6) 80.9 (19.3) 0.827 87.3 (19.0) 84.2 (19.3) <0.001
Controller:total asthma med
ratio 0.5, n (%)
e e e 3740 (58.9) 7425 (58.4) 0.384
Mean daily SABA dose, n (%)d
0e100 mg/d 4482 (59.6) 2241 (59.6) n/a 1313 (20.7) 2626 (20.7) n/a
101e200 mg/d 1700 (22.6) 850 (22.6) 1532 (24.1) 3064 (24.1)
201e400 mg/d 800 (10.6) 400 (10.6) 1660 (26.1) 3320 (26.1)
401 mg/d 544 (7.2) 272 (7.2) 1850 (29.1) 3700 (29.1)
Mean daily ICS dose, n (%)d
0e100 mg/d e e e 738 (11.6) 1476 (11.6) n/a
101e200 mg/d e e 1667 (26.2) 3334 (26.2)
201e400 mg/d e e 2225 (35.0) 4450 (35.0)
401 mg/d e e 1725 (27.1) 3450 (27.1)
Long-acting b-agonist used, n (%) 68 (0.9) 18 (0.5) 0.016 703 (11.1) 1600 (12.6) 0.002
Oral corticosteroid courses, n (%)
0 6096 (81.0) 3048 (81.0) n/a 5764 (90.7) 11,528 (90.7) n/a
1 1106 (14.7) 553 (14.7) 431 (6.8) 862 (6.8)
2 324 (4.3) 162 (4.3) 160 (2.5) 320 (2.5)
Total severe exacerbations, n (%)
0 6059 (80.5) 3036 (80.7) 0.779 5744 (90.4) 11,506 (90.5) 0.639
1 1217 (16.2) 598 (15.9) 473 (7.4) 917 (7.2)
2 250 (3.3) 129 (3.4) 138 (2.2) 287 (2.3)
Non-emergency asthma consultations, n (%)
0 3856 (51.2) 1928 (51.2) n/a 2692 (42.4) 5384 (42.4) n/a
1 2908 (38.6) 1454 (38.6) 2718 (42.8) 5436 (42.8)
2 640 (8.5) 320 (8.5) 729 (11.5) 1458 (11.5)
3 122 (1.6) 61 (1.6) 216 (3.4) 432 (3.4)
Asthma prescriptions, n (%)
0e1 3651 (48.5) 1734 (46.1) 0.006 445 (7.0) 903 (7.1) 0.081
2e3 2043 (27.1) 1062 (28.2) 1594 (25.1) 3371 (26.5)
4e5 813 (10.8) 427 (11.3) 1465 (23.1) 2843 (22.4)
6 1019 (13.5) 540 (14.4) 2851 (44.9) 5593 (44.0)
1 Consultations for LRTI, n (%) 1425 (18.9) 735 (19.5) 0.429 721 (11.3) 1389 (10.9) 0.375
Oropharyngeal candidiasis, n (%)e 60 (0.8) 30 (0.8) 1.0 119 (1.9) 207 (1.6) 0.217
BDP Z beclometasone dipropionate; LP Z larger-particle; LRTI Z lower respiratory tract infection; n/a Z not applicable (matching
criterion); PEF Z peak expiratory flow; SABA Z short-acting b2-agonist.
a Conditional logistic regression.
b Asthma was identified for all patients as either a database read code for asthma or 2 prescriptions for asthma during the baseline
year, with no code for another chronic respiratory condition.
c Patients with recorded PEF in the extrafine and larger-particle beclometasone cohorts totalled 2047 (27%) and 928 (25%), respec-
tively, in the initiation population and 4098 (65%) and 8939 (70%), respectively, in the switch population.
d The SABA dose is the salbutamol dose equivalent (standard dose in UK is 200 mg).
e Diagnosis of or therapy for oropharyngeal candidiasis (thrush).
992 D. Price et al.the four study cohorts by examining outcomes (no loss of
asthma control and exacerbations) according to 1) actual
ICS dose consumed and 2) adherence. The comparative
effects of treatment with extrafine beclometasone and
larger-particle beclometasone were consistent across ICS
dose as well as adherence during the outcome year (Figs. 3
and 4).Spacer device prescribing was significantly less frequent
in the extrafine beclometasone cohort of the initiation pop-
ulation and more frequent in the extrafine beclometasone
cohort of the switch population (Table 4). Fewer patients in
the two extrafine beclometasone cohorts developed oral
candidiasis as compared with the corresponding larger-
particle beclometasone cohort (Table 4), although after
Figure 1 Inhaled corticosteroid dose (categorised) on the
index date for patients with asthma (a) initiating beclometa-
sone or (b) switching to beclometasone. The comparison be-
tween treatment cohorts for categorised dose was statistically
significant (p < 0.001) for the initiation population but not for
the switch population (p Z 0.214). The extrafine beclometa-
sone dose is shown in proportion to double the dose of larger-
particle beclometasone in accordance with licensing recom-
mendations. BDP Z beclometasone dipropionate.
Extrafine versus larger-particle BDP for asthma 993adjustment for confounding factors the differences between
cohorts were no longer significant (Fig. 2).
Exploratory analysis
Extrapolating from 2007 data in the OPCRD, we calculated
that each year 511 adults would initiate ICS therapy for
asthma and 3142 adults would switch from CFC to HFA ICS in
the average PCT population size of 340,900 patients. For
511 adults with asthma initiating ICS, we calculated that
prescribing extrafine instead of larger-particle beclometa-
sone would result each year in 4 fewer patients being
hospitalised for respiratory-related illness and 8 fewer pa-
tients receiving a course of oral corticosteroids. For 3142
adults with asthma, switching from CFC to extrafine instead
of larger-particle HFA-beclometasone would result each
year in 15 fewer patients being hospitalised for respiratory-
related illness and 31 fewer patients receiving a course of
oral corticosteroids.Discussion
In this matched cohort study evaluating real-life asthma
management, primary care patients prescribed beclometa-
sone in an extrafine formulation, as compared with a larger-
particle formulation, had significantly greater odds of no loss
of asthma control and of the more stringent database mea-
sure of no loss of asthma control plus limited SABA use. This
difference was recorded both for patients initiating inhaled
beclometasone therapy and for those switching to beclo-
metasone therapy at a dose equivalent to that of their prior
ICS. In addition, adherence to therapy and cumulative ICS
dose received were significantly higher during the outcome
year in the extrafine beclometasone cohorts, whilst the odds
of respiratory-related hospitalisations were significantly
lower. The adjusted risk of severe exacerbations was not
significantly different between treatment cohorts.
The fact that the comparative effects of treatment with
extrafine beclometasone and larger-particle beclometasone
were consistent across ICS dose consumed as well as adher-
ence during the outcome year reassures us that differences
in outcomes were due to treatments. The differences in
outcomes between the two treatment cohorts suggest
greater success when using extrafine beclometasone in
attaining key goals of asthma therapy, namely, maintaining
asthma control while minimising hospitalisations. Moreover,
study results were consistent for both the initiation and
switch populations. Whilst we did not record a large effect,
one would not expect a large difference when comparing
matched cohorts and the same class of therapy for patients
with only limited scope to show difference.
We designed the coprimary measure of no loss of asthma
control to capture evidence of an exacerbation (oral corti-
costeroids or hospital visits for asthma) as defined by the ERS/
ATS Task Force,23 in addition to antibiotic prescribing for
lower respiratory tract infection, common for patients pre-
senting with an acute asthma exacerbation.30e32 The differ-
ence in findings for no loss of asthma control versus
exacerbation measures could be explained by this difference
(inclusion of antibiotic prescribing) as well as the fact that
asthma control is a dichotomy (yes versus no), while the
exacerbation rate is a continuum and thus distinguishes be-
tween1versusmore than1events.Weconstructed theno loss
of asthma control plus limited SABA use measure to capture
both impairment as well as risk of future exacerbations, the
two accepted components of asthma control.33 The Global
Initiative for Asthma (GINA) definition of asthma control in-
cludes rescue therapy use, symptoms, functional limitation,
and pulmonary function33; however, only rescue therapy use
can be determined in a database study such as ours. We
included a cut-point of 200 mg/d salbutamol, which works
out to<4 canisters/year, an amount that is on the lowendof a
validated 4-level long-term control scale using SABA pre-
scriptions from computerised pharmacy data, in which a sig-
nificant linear relationship was seen between this scale (0e2,
3e6, 7e12, and>12 SABA canisters/year) and impairment as
well as subsequent risk of exacerbations.34
Results of our exploratory analysis suggest that each year
in anaveragePCTpopulation of 340,900patients, prescribing
extrafine instead of larger-particle beclometasone would
prevent 4 hospitalisations amongst 511 adults initiating ICS
and 15 hospitalisations amongst 3142 switching ICS; 8 and 31
Table 4 Unadjusted outcomes over 1 year after patients with asthma received their first inhaled corticosteroid prescription as
extrafine or larger-particle beclometasone or switched inhaled corticosteroid therapy to extrafine or larger-particle
beclometasone.
Outcome Initiation population Switch population
Extrafine BDP
(n Z 7526)
LP BDP
(n Z 3763)
Extrafine BDP
(n Z 6355)
LP BDP
(n Z 12,710)
No loss of asthma controla 5729 (76.1) 2778 (73.8) 5150 (81.0) 10,106 (79.5)
No loss of asthma control plus
limited SABA use
2953 (39.2) 1405 (37.3) 1980 (31.2) 3740 (29.4)
1 Severe exacerbationa 790 (10.5) 447 (11.9) 546 (8.6) 1226 (9.6)
2 severe exacerbations 321 (4.3) 167 (4.4) 196 (3.1) 380 (3.0)
1 lower respiratory episode requiring
medical resource use
1063 (14.1) 575 (15.3) 823 (13.0) 1687 (13.3)
2 lower respiratory episodes 539 (7.2) 287 (7.6) 363 (5.7) 840 (6.6)
1 respiratory-related hospitalisation 105 (1.4) 88 (2.3) 58 (0.9) 176 (1.4)
Mean daily SABA dose >200 mg/dc 3812 (50.7) 1952 (51.9) 4017 (63.2) 8244 (64.9)
p Valueb p Valueb
Median (IQR) daily inhaled
corticosteroid dose (adjusted
to dose-equivalence), mg/dc
329 (220e548) 274 (164e438) <0.001 384 (219e658) 329 (219e559) 0.012
Mean daily inhaled corticosteroid dosec
1e50 EF/1e100 LP, mg/d 35 (0.5) 153 (4.1) <0.001 54 (0.8) 293 (2.3) <0.001
51e100 EF/101e200 LP, mg/d 1415 (18.8) 1031 (27.4) 844 (13.3) 2163 (17.0)
101e200 EF/201e400 LP, mg/d 2998 (39.8) 1416 (37.6) 2350 (37.0) 4663 (36.7)
201e400 EF/401e800 LP, mg/d 2248 (29.9) 869 (23.1) 2224 (35.0) 3774 (29.7)
401 EF/801 LP, mg/d 830 (11.0) 294 (7.8) 883 (13.9) 1817 (14.3)
1 oral corticosteroid course 1088 (14.5) 605 (16.1) 0.051 721 (11.3) 1574 (12.3) 0.156
1 consultation for LRTI 876 (11.6) 474 (12.6) 0.142 663 (10.4) 1426 (11.2) 0.098
Long-acting b-agonist prescribed 1158 (15.4) 666 (17.7) 0.002 1104 (17.4) 2305 (18.1) 0.186
Spacer device prescribed 1826 (24.3) 1275 (33.9) <0.001 1023 (16.1) 1665 (13.1) <0.001
Controller-to-total asthma
med ratio 0.5
4849 (64.4) 2540 (67.5) 0.001 3839 (60.4) 7866 (61.9) 0.018
Change in ICS 715 (9.5) 596 (15.8) <0.001 379 (6.0) 832 (6.5) 0.119
Oral candidiasisd 194 (2.6) 140 (3.7) 0.001 146 (2.3) 340 (2.7) 0.119
Data are presented as n (%) unless otherwise specified.
BDP Z beclometasone dipropionate; EF Z extrafine; IQR Z interquartile range; LP Z larger-particle; LRTI Z lower respiratory tract
infection; SABA Z short-acting b-agonist.
a Co-primary endpoints. See Table 1 for definitions of study endpoints.
b Conditional logistic regression.
c The SABA dose is the salbutamol dose equivalent. The daily inhaled corticosteroid dose consumed during the outcome year was
calculated as the dispensed amount divided by 365. Median (IQR) extrafine BDP doses are doubled (extrafine BDP is prescribed, per
licensing, at half the larger-particle BDP dose).
d Diagnosis of or therapy for oropharyngeal candidiasis (thrush).
994 D. Price et al.fewer patients, respectively, would require a course of oral
corticosteroids. These differences would be achieved at no
additional cost.
The results of the present study are compatible with
those of prior observational studies suggesting that better
asthma outcomes are achievable with extrafine as
compared with larger-particle size ICS delivered by a
pressurised metered-dose inhaler.20,35 In earlier studies
comparing delivery of extrafine beclometasone with de-
livery from CFC-driven, pressurised metered-dose inhalers,
use of the extrafine formulation resulted in lower oropha-
ryngeal deposition in patients with asthma and healthy
volunteers, suggesting the possibility of a reduced risk of
oropharyngeal candidiasis (thrush).4e6 In the present study
we did not observe a significant difference betweentreatment cohorts in the adjusted risk of thrush, although
the comparison in this case was not with devices using
different propellants.
Our data do not provide information regarding the pre-
cise mechanisms behind the better asthma outcomes with
extrafine beclometasone therapy. One might speculate that
they at least partly reflect previously demonstrated,
improved lower airway deposition of the drug when deliv-
ered in extrafine particles even in patients with relatively
poor coordination of inhalation and actuation of a metered-
dose inhaler.6 A reason proposed for the relatively stable
and better deposition of beclometasone delivered in
extrafine particles, as compared with delivery by a CFC-
driven device (lung deposition, 4e7%), is that the extra-
fine particles remain suspended for longer during
Figure 2 Adjusted outcome measures for study endpoints over 1 year after the first ICS prescription for (a) the initiation pop-
ulation and (b) the switch population. The larger-particle beclometasone cohort is the comparator, with adjusted risk ratio/odds
ratio set at 1.0. Adjustments for baseline confounding factors: *Adjusted for smoking status, rhinitis diagnosis/therapy, inpatient
admissions, and OPD attendance. yAdjusted for LABA use, number of LRTI consultations, and smoking status. zAdjusted for number
of asthma consultations and inpatient admissions. xAdjusted for number of prescriptions for asthma or allergy drugs, number of
asthma consultations, and time between asthma diagnosis and the index date. UOR of a higher categorised mean daily SABA dose,
adjusted for time between diagnosis and the index date, smoking status, A&E attendance, and number of SABA prescriptions. #OR
of a higher categorised adherence to ICS therapy, adjusted for time between diagnosis and the index date and number of pre-
scriptions for asthma or allergy drugs.^Adjusted for age, time between diagnosis and the index date, number of LRTI consultations,
and baseline incidence of oral candidiasis. **Adjusted for LABA use and number of LRTI consultations, inpatient admissions, and
OPD attendance for asthma. yAdjusted for LABA use, number of SABA prescriptions and LRTI consultations, and smoking status.
zzAdjusted for LABA use, adherence to ICS therapy, and number of inpatient admissions. xxAdjusted for number of inpatient ad-
missions. UUOR of a higher categorised mean daily SABA dose, adjusted for time between diagnosis and the index date, and number
of SABA prescriptions. ##OR of a higher categorised adherence to ICS therapy, adjusted for time between diagnosis and the index
date, LABA use, and baseline adherence to ICS therapy. A^djusted for baseline incidence of oral candidiasis. A&E Z Accident and
Emergency; BDP Z beclometasone dipropionate; ICS Z inhaled corticosteroid; LABA Z long-acting b-agonist; LRTI Z lower res-
piratory tract infection; OPD Z Outpatient Department; SABA Z short-acting b-agonist. Hospital attendance and admission, and
OPD and A&E attendance, were for asthma or lower respiratory reasons.
Extrafine versus larger-particle BDP for asthma 995inspiration and thus are more likely to reach the lungs, even
with poorly coordinated inhaler technique, as long as the
breath is held after inhalation.6 It is likely that this
reasoning can be applied when comparing HFA-driven
extrafine versus larger-particle beclometasone formula-
tions, although to our knowledge there is no published
comparison of their deposition characteristics.In this study, patients receiving extrafine beclometasone
also appeared to show significantly better adherence to
therapy compared with those receiving larger-particle
beclometasone. Again the present data provide no infor-
mation as to the reasons for this better adherence, but one
might speculate that it reflects better inhaler technique
tolerance (a softer, warmer and longer duration spray) or
Figure 3 Proportion of patients in the initiation population, by treatment cohort, who achieved the no loss of asthma control
measure during the outcome year, (a) categorised by consumed ICS dose (i.e., prescribed ICS divided by 365, with EF-BDP dose
doubled in line with the recommended 1:2 prescribing dose ratio with LP-BDP) and (b) by adherence to ICS therapy during the
outcome year. Panel c depicts exacerbation rates by consumed ICS dose (EF-BDP dose doubled), and panel d depicts exacerbation
rates by adherence to ICS. Patient count percentages may not equal 100% because of rounding. EF-BDPZ extrafine beclometasone
dipropionate; ICS Z inhaled corticosteroid; LP-BDP Z larger-particle beclometasone dipropionate.
996 D. Price et al.the possibility that patients prescribed the extrafine prep-
aration were more likely to be instructed to take it regu-
larly and/or monitored more closely while doing so. We
cannot rule out the possibility that prescribers of extrafine-
particle beclometasone formulations are more knowledge-
able and interested in asthma care than their counterparts.
However, we identified no other indicators of practice or
physician differences; indeed, the fact that similar pro-
portions of patients in each cohort (e.g., 65% and 70% inswitch population extrafine- and large-particle beclome-
tasone cohorts, respectively) had recorded PEF values
suggests no differences.
In addition to increased adherence, patients in the
extrafine beclometasone cohorts received significantly
higher median daily doses of beclometasone over the
outcome year than those in the larger-particle beclometa-
sone cohorts (compared using larger-particle equivalent
doses).1,36 This might reflect the observed improved
Figure 4 Proportion of patients in the switch population, by treatment cohort, who achieved the no loss of asthma control
measure during the outcome year, (a) categorised by consumed ICS dose (i.e., prescribed ICS divided by 365, with EF-BDP dose
doubled in line with the recommended 1:2 prescribing dose ratio with LP-BDP) and (b) by adherence to ICS therapy during the
outcome year. Panel c depicts exacerbation rates by consumed ICS dose (EF-BDP dose doubled), and panel d depicts exacerbation
rates by adherence to ICS. Patient count percentages may not equal 100% because of rounding. EF-BDPZ extrafine beclometasone
dipropionate; ICS Z inhaled corticosteroid; LP-BDP Z larger-particle beclometasone dipropionate.
Extrafine versus larger-particle BDP for asthma 997adherence (patients taking doses as instructed whether or
not theywere necessary for disease control), or the fact that
patients needed a higher dose of the extrafine preparation
for disease control because it is not actually twice as
effective as larger-particle beclometasone, at least in some
patients, or a mixture of both. Further information gained
on examining the doseeresponse relationships indicates
that patients whowere prescribed extrafine beclometasoneexperienced similar or better control than those prescribed
larger-particle beclometasone at similar levels of adher-
ence or ICS dose consumed, with increasing benefits of the
extrafine particle being evident at the higher doses required
by less-controlled patients (please see Figs. 3 and 4). We
note that patients appeared to self-titrate, showing more
adherence to therapy with worse levels of control, an
observation also reported by others.37,38
998 D. Price et al.We feel that the significantly higher mean index date
doses for the extrafine beclometasone cohort of the initi-
ation population most likely reflect the earlier index dates
for extrafine beclometasone, at a time when asthma
guidelines recommended starting ICS at a high dose and
then stepping down.39,40 By contrast, patients in the switch
population were prescribed extrafine or larger-particle
beclometasone at a dose equivalent to their existing dose.
The importance of real-life findings for guiding clinical
practice is increasingly recognised.14,15,41 The strengths of
this study include its large size and its use of representative
data from general practice, where over 90% of patients with
asthma are managed in the UK.42 We studied patients pre-
scribed their first ICS, a relatively uniform population with
regard to degree of experience using inhaler devices, as well
as those newly switched to inhaled beclometasone, all of
whom had prior experience using ICS. Outcome assessment
over a full year helped to limit the influence of seasonal ef-
fects and to capture less frequent events such as hospital-
isations.While we cannot rule out the possibility that smokers
or ex-smokers with concomitant COPD were included in the
study, the percentages of smokers and ex-smokers over
40 years of age were similar in the treatment cohorts of each
study population; thus, the likelihood of including patients
with COPD would be roughly the same in each cohort.
The limitationsof our studyfindingsare thosecommontoall
observational studies, in particular the lack of a placebo group
and the absence of randomised assignment to treatment co-
horts, allowing the possibility of treatment selection bias and
other potential confounding effects. Using a matched cohort
design helped us to minimise these effects; and we made sta-
tistical adjustments to address minor residual confounding
that existed after matching. Nonetheless, the index prescrip-
tiondatesweresignificantlydifferentbetweenthetwocohorts
because of the earlier availability of extrafine beclometasone
(1998 versus 2006 for larger-particle HFA-delivered beclome-
tasone). While this may have influenced the typical, initial
prescribed dose of ICS, the only other major change in asthma
therapyover this timeperiodwas the increasinglyearlieruseof
add-on therapy, not a factor in this study.
In conclusion, our findings in this matched cohort study
of patients receiving the same ICS molecule delivered using
the same device and propellant allow the empirical
observation that the use of extrafine beclometasone con-
tributes to improved real-life outcome measures when
managing asthma in primary care. What this study does not
tell us is precisely why, although one might speculate that
better and deeper airways penetration, better tolerance of
sub-optimal inhaler technique, better adherence with
prescribing instructions, and a better informed patient
clientele may be contributory factors.Funding
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